R21/Matrix-M, developed at the University of Oxford, is approved for use in children between the ages of five months and three years.
Ghana has become the first country in the world to approve the permanent use of the British R21/Matrix-M malaria vaccine. This was reported on April 13 by the Daily Graphic news portal.
Ghanaian regulators have approved the drug’s use for children aged five months to three years, the age group at highest risk of dying from malaria.
It noted that the vaccine decision “is the culmination of 30 years of research.”
Remember that R21 / Matrix-M was created at Oxford University. In recent years, its clinical trials have been conducted in several African countries, including Ghana, Kenya, Malawi and Burkina Faso. Scientists complete the analysis of the test work performed.
According to preliminary findings, the effectiveness of the vaccine in protecting the child’s body from the causative agent of malaria is up to 80%.
It was earlier reported that the Serum Institute of India has agreed to manufacture up to 200 million doses of R21/Matrix-M per year. The vaccine plant is being built in Ghana’s capital, Accra
Malaria is one of the most prevalent diseases in Africa. According to the WHO, approximately 620 thousand people become its victims every year, mostly in childhood. At the same time, 93% of deaths occur in African countries.
A resident of the Rivne region was diagnosed with malaria
news Correspondent.net on Telegram. Subscribe to our channel Athletistic
Source: korrespondent
I am David Wyatt, a professional writer and journalist for Buna Times. I specialize in the world section of news coverage, where I bring to light stories and issues that affect us globally. As a graduate of Journalism, I have always had the passion to spread knowledge through writing.